HBM Holdings (HKG:2142) said it expects to report a profit of between HK$532 million to about HK$579 million for the six months ended 30 June, according to a Monday Hong Kong bourse filing.
The improvement was mainly driven by proceeds from strategic collaborations, including a global partnership with AstraZeneca that contributed around $175 million from subscription shares, upfront payments, milestones, and option fees.
Interim results are expected by the end of August.
Shares of the company were down about 4% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.